- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
Simcyp provides platforms for modelling and simulation of drug absorption, distribution, metabolism and excretion (ADME) in virtual human populations and virtual laboratory animals. The company's flagship product the "Simcyp Population-based ADME Simulator" is used by the world's top pharmaceutical companies and is recognised as the industry's most sophisticated platform for the simulation of drug-drug interactions. Simcyp also runs educational workshops, provides consultancy services and supports academic and drug regulatory research through the provision of not-for-profit Simulator licenses to over sixty associate institutions.
The Mechanistic in vitro-in vivo extrapolation of ADME with expertise in multiple drug-drug interaction at enzyme and transporters level, PBPK/PD modelling, system biology approaches to disease modelling in oncology, rheumatoid arthritis and CNS areas including Alzheimer's disease,system/software architecture design, software development, parallel and distributed computing, and PopPK data analysis, scientific data management, application of different software packages e.g. NONMEM, Trial Simulator 2, SAS, S-PLUS, petrinet-variant simulation software like Cell-Simulator/Genomic Objects using CSML, SBML, C++, Java, C#, ASP, Fortran.